Treatment of psoriasis with recombinant human LFA3-antibody fusion protein: a multi-center, randomized, double-blind trial in a Chinese population.

@article{Yan2011TreatmentOP,
  title={Treatment of psoriasis with recombinant human LFA3-antibody fusion protein: a multi-center, randomized, double-blind trial in a Chinese population.},
  author={Heng Yan and Min Tang and Yi You and J. Yu and Jiang-an Zhang and Xiao-Hong Li and Jian-Fang Sun and Yi-qun Jiang and Hao Chen and Zai-Pei Guo and Lin Xiong and Wei He and Zhi Li and Jun Gu and Chun-fang Gao and Zhi-li Guo and Tian-wen Gao and Gang Sam Wang and Xian-ping Li and Jing Li and Fei Hao and Ya-jun Guo},
  journal={European journal of dermatology : EJD},
  year={2011},
  volume={21 5},
  pages={737-43}
}
To evaluate clinical efficacy and safety of injectable recombinant human LFA3-antibody fusion protein (rhLFA3-IgFP), a multi-center, randomized, double-blind, double-dummy, parallel-controlled clinical trial was performed in 212 cases of moderate to severe psoriasis. Intramuscular injection of rhLFA3-IgFP (15 mg/week) and oral administration of blank dummy methotrexate at the dose of 7.5 mg/week was performed in the patients in the experimental group, and control patients were orally… CONTINUE READING

From This Paper

Topics from this paper.